# ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Source: https://onco.cc/trials/nct04829604/  
OnCo record `nct04829604` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ARX788 in HER2-positive breast cancer, run by Ambrx, Inc., active and no longer recruiting.

## Summary

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) is a phase 2 interventional study registered as NCT04829604 by Ambrx, Inc., with 72 participants enrolled, started 2021-10-26 and due to reach its primary completion in 2026-12. Interventions recorded: ARX788.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04829604
- Phase: 2
- Setting: A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
- Sponsor: Ambrx, Inc.
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT04829604: https://clinicaltrials.gov/study/NCT04829604

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [ARX788](https://onco.cc/drugs/arx788/)

---
JSON: https://onco.cc/api/v1/entities/nct04829604.json